Indivior signs deal to sell schizophrenia drug Perseris in Canada
Perseris, launched in the United States in February, is approved by the FDA for the treatment of schizophrenia in adults.
U.S: British drugmaker Indivior Plc on Thursday signed a licensing agreement with HLS Therapeutics Inc for the sale of its schizophrenia drug Perseris in Canada.
Perseris, launched in the United States in February, is approved by the FDA for the treatment of schizophrenia in adults.
The drug delivers its active ingredient, risperidone, in an extended-release delivery system with no loading doses or oral supplementation recommended.
Indivior has been looking to reduce its dependence on its best-selling Suboxone film after the opioid addiction treatment was hit by steep market share losses to generic rivals.
Indivior, which gets most of its revenue from Suboxone in the United States, was indicted last month for illegal marketing of Suboxone in the U.S. and was fined $3 billion.
Read Also: Indivior to launch Sublocade; maintains revenue forecast
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd